What happens when every health app has the same rPPG engine?

Shared rPPG engine health apps commoditization is no longer a hypothetical. It is starting to look like the normal shape of the market. Once multiple health apps license the same camera-based vitals layer, heart rate capture and related workflows stop being a product story by themselves. For founders, telehealth PMs, and hospital IT buyers, the real question changes fast: if the sensing layer is available to everyone, what still counts as defensible?

"For the first time, AI-enabled startups captured a majority (62%) of digital health venture funding in H1 2025." — Rock Health, H1 2025 market overview: Proof in the pudding

Shared rPPG engine health apps commoditization changes what buyers should evaluate

When teams first look at rPPG, they often focus on the engine. That makes sense at the beginning. The engine is the new thing. It measures vitals from a camera feed, and it feels like the hardest part to build.

But once that engine is available through white-label licensing, API access, or OEM partnerships, the market stops rewarding novelty alone. It starts rewarding packaging, workflow fit, integration quality, trust, and speed of deployment.

That is not unique to rPPG. McKinsey argued in its digital health ecosystem work that platform value increasingly comes from how products fit into care delivery, data flows, and operating models rather than from a single isolated feature. In plain English: once enough companies can buy the same core capability, buyers stop paying extra just because it exists.

There is also a technical reason for this shift. In a July 2024 Frontiers in Bioengineering and Biotechnology review, Wei Chen, Zhe Yi, Lincoln Jian Rong Lim, Rebecca Qian Ru Lim, and colleagues described how deep learning and remote photoplethysmography are advancing contactless measurement across heart rate, respiratory rate, oxygen saturation, heart-rate variability, and blood pressure research. That breadth is impressive. It also hints at a future where the base measurement layer becomes a reusable platform component rather than a rare product asset.

Question buyers ask	When rPPG is rare	When many apps share the same engine
What matters first?	Whether camera-based vitals are possible at all	Whether the product fits real workflows and business goals
Main source of differentiation	Access to the sensing capability	User experience, data routing, reporting, brand control, and service design
Procurement focus	Core feature novelty	Integration depth, admin controls, security posture, and speed to launch
Commercial risk	Choosing unproven technology	Choosing an interchangeable vendor relationship
What gets commoditized?	Less	The base measurement layer itself

This is where some teams misread the market. They assume commoditization is bad news. It is not automatically bad. It usually means the buyer has more options and the winning product team has to do more than wave at the core engine.

A shared rPPG layer can still be valuable. It just is not enough.

Where value moves after the engine becomes common

Once multiple vendors can deliver a comparable contactless vitals layer, value tends to move upward in the stack.

It usually shifts into areas like these:

• branded patient or member experience
• workflow design for clinicians, call centers, or care coordinators
• enterprise integrations with EHR, CRM, identity, and analytics systems
• reporting, triage logic, and operational dashboards
• deployment model flexibility across multiple customer accounts or business units
• contracting terms around data ownership, portability, and support

That pattern lines up with what Rock Health reported in H1 2025. The most funded digital health value propositions were non-clinical workflow, clinical workflow, and data infrastructure. That is a useful signal. Investors are still backing infrastructure, but they are putting even more money into the layers that determine whether infrastructure actually gets used.

There is an older lesson here too. In their 2018 JMIR mHealth and uHealth meta-analysis, Benjamin De Ridder, Bart Van Rompaey, Jarl K. Kampen, Steven Haine, and Tinne Dilles found good agreement between smartphone photoplethysmography apps and validated methods for adult heart-rate measurement at rest. Once a technical capability starts showing repeatable performance across many implementations, competition usually moves away from the basic proof point and toward the product around it.

I keep coming back to that. In digital health, a feature can be clinically interesting long before it becomes commercially scarce.

Industry applications

Digital health startups

For startups, a shared engine can be a gift and a problem at the same time. The gift is obvious: they can launch faster without hiring a deep signal-processing team. The problem is that their competitors can do the same.

That makes positioning more demanding. A startup cannot rely on "we added camera vitals" as its whole story for long. It needs a sharper answer:

• Which user segment is it designed for?
• Which workflow gets simpler or faster?
• Which operator inside the buyer organization gets measurable value?
• What part of the customer experience actually feels different?

Telehealth platform product managers

Telehealth PMs usually care less about the engine in isolation and more about whether it disappears neatly into the product. They want the scan flow to feel native, the data to route cleanly, and the admin controls to behave predictably across teams.

If many apps share the same rPPG engine, the evaluation shifts toward integration depth:

• Does it work inside existing onboarding and visit flows?
• Can alerts, thresholds, and permissions be configured by account?
• Can the data be exposed to downstream systems without awkward middleware?

That is why posts like White-Label vs Embedded SDK: Choosing the Right Integration Depth matter more than abstract debates about technical novelty.

Hospital IT and enterprise buyers

Enterprise buyers rarely want a clever demo. They want a manageable operating model.

If the underlying engine is no longer unique, hospital IT will focus on practical questions:

• who owns the data
• how access is logged and audited
• how the product behaves across multi-site environments
• how quickly a new department or program can be added
• what happens if the buyer wants to migrate later

That is the part many sales decks underplay. Interchangeable base technology makes governance and deployment design more important, not less.

Current research and evidence

The research base around rPPG is broader than it was a few years ago, and that itself pushes the market toward standardization.

Chen and colleagues' 2024 Frontiers review described contactless physiological measurement as a fast-moving area spanning conventional signal extraction and newer deep-learning methods. The authors also noted an important caution: standardization is still incomplete. That means the market is in an awkward middle stage. The technology is credible enough to spread, but not so settled that implementation details stop mattering.

De Ridder and coauthors' meta-analysis is useful for another reason. It showed that smartphone-based photoplethysmography could align well with validated methods in adults at rest, with a pooled mean difference of -0.32 beats per minute and Pearson correlations at or above 0.90 in adult populations. That kind of evidence does not tell buyers which vendor to pick. It tells them the category itself is becoming easier to trust and compare.

Rock Health's H1 2025 market overview adds the commercial side of the picture. Digital health companies raised $6.4 billion across 245 deals in the first half of 2025, and AI-enabled startups captured 62% of that funding. More telling for this topic, workflow and data infrastructure categories pulled in a large share of the capital. Investors seem to be saying that the winning companies will not be the ones with only a sensing layer. They will be the ones that turn that layer into usable systems.

Source	What it says	Why it matters here
Chen et al., Frontiers (2024)	rPPG and deep learning now support a broad set of contactless measurement use cases	Broad capability makes a shared engine model more plausible
De Ridder et al., JMIR (2018)	Smartphone PPG apps showed good agreement with validated heart-rate methods in adults at rest	The core measurement category is increasingly comparable across implementations
Rock Health, H1 2025	$6.4B raised in H1 2025; 62% went to AI-enabled startups; workflow and data infrastructure led funding	Capital is flowing toward products that operationalize infrastructure
McKinsey digital health ecosystem analysis	Health platform value depends on ecosystem fit, data flow, and workflow integration	Buyers should judge the system around the engine, not only the engine

For buyers, the takeaway is pretty simple: ask less about whether an rPPG engine exists and more about what the surrounding platform lets your organization do.

The future of shared rPPG engines

I do not think the market is heading toward one giant winner that supplies every health app. It looks more fragmented than that. But I do think the base rPPG layer will feel more like cloud infrastructure than bespoke invention.

If that happens, several things follow.

First, white-label and OEM models become more attractive because they let companies launch quickly without pretending they need to own every layer. Second, vendors will have to prove they can support multiple operating models, not just multiple logos. Third, buyers will push harder on data portability and contractual exit paths because nobody wants to discover too late that a commodity engine came with non-commodity switching costs.

That makes the next phase of competition more interesting, honestly. If everyone can access a similar sensing capability, product teams have to be clearer about what business they are really in. Care workflow? Member engagement? Platform infrastructure? Enterprise deployment? Population analytics? Those answers matter more than the phrase "camera-based vitals" on a homepage.

If you are evaluating platform options, it is also worth reading What Is a White-Label Vitals Engine? Build vs License Explained and White-Label vs Build From Scratch: Cost and Timeline Compared. Both get at the same underlying issue from different angles: the engine matters, but the surrounding business model matters more.

Frequently asked questions

Does sharing the same rPPG engine make health apps indistinguishable?

Not by itself. Apps become harder to distinguish at the measurement layer, but they can still differ in workflow design, analytics, reporting, implementation speed, integration model, and brand experience.

What becomes the main differentiator after rPPG is commoditized?

Usually the differentiators move into integration quality, user experience, enterprise controls, data portability, and the specific care or operational workflows the product supports.

Is a white-label rPPG platform still worth considering if other apps use similar infrastructure?

Yes. For many teams, the goal is not to own the engine. The goal is to launch a branded, workable product quickly and spend internal resources on distribution, service design, and customer experience.

What should hospital IT or telehealth buyers ask vendors first?

Start with deployment and governance questions: data ownership, API access, permissioning, audit trails, multi-tenant support, onboarding effort, and contract terms for future migration.

Circadify is addressing this market with white-label and custom-branded platform options for teams that want camera-based vitals without building the full infrastructure stack themselves. For partnership discussions, see Partnership inquiry → circadify.com/custom-builds.